NZ619478B2 - Treatment of excessive menstrual bleeding associated with uterine fibroids - Google Patents
Treatment of excessive menstrual bleeding associated with uterine fibroids Download PDFInfo
- Publication number
- NZ619478B2 NZ619478B2 NZ619478A NZ61947812A NZ619478B2 NZ 619478 B2 NZ619478 B2 NZ 619478B2 NZ 619478 A NZ619478 A NZ 619478A NZ 61947812 A NZ61947812 A NZ 61947812A NZ 619478 B2 NZ619478 B2 NZ 619478B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- cdb
- metabolite
- treatment
- ulipristal
- use according
- Prior art date
Links
- 230000002175 menstrual Effects 0.000 title claims abstract description 46
- 206010018987 Haemorrhage Diseases 0.000 title claims abstract description 44
- 206010046798 Uterine leiomyoma Diseases 0.000 title claims abstract description 44
- 230000000740 bleeding Effects 0.000 title claims abstract description 44
- 231100000319 bleeding Toxicity 0.000 title claims abstract description 44
- OOLLAFOLCSJHRE-ZHAKMVSLSA-N ulipristal acetate Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(OC(C)=O)C(C)=O)[C@]2(C)C1 OOLLAFOLCSJHRE-ZHAKMVSLSA-N 0.000 claims abstract description 75
- 239000002207 metabolite Substances 0.000 claims abstract description 43
- 206010053648 Vascular occlusion Diseases 0.000 claims abstract description 25
- 201000009274 endometriosis of uterus Diseases 0.000 claims abstract description 18
- 229960000499 ulipristal acetate Drugs 0.000 claims abstract description 15
- 238000004519 manufacturing process Methods 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 7
- HKDLNTKNLJPAIY-WKWWZUSTSA-N (8S,11R,13S,14S,17R)-17-acetyl-11-[4-(dimethylamino)phenyl]-17-hydroxy-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)C(C)=O)[C@]2(C)C1 HKDLNTKNLJPAIY-WKWWZUSTSA-N 0.000 claims abstract 7
- 229960000200 ulipristal Drugs 0.000 claims description 41
- 230000037227 Blood Loss Effects 0.000 claims description 18
- 210000000685 Uterine Artery Anatomy 0.000 claims description 16
- 208000005641 Adenomyosis Diseases 0.000 claims description 14
- 238000002604 ultrasonography Methods 0.000 claims description 8
- 238000010606 normalization Methods 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 5
- 230000027758 ovulation cycle Effects 0.000 claims description 2
- 238000007674 radiofrequency ablation Methods 0.000 claims description 2
- 239000002379 progesterone receptor modulator Substances 0.000 description 41
- 201000010260 leiomyoma Diseases 0.000 description 32
- 201000010099 disease Diseases 0.000 description 24
- 150000003839 salts Chemical class 0.000 description 23
- 239000011780 sodium chloride Substances 0.000 description 21
- 238000000034 method Methods 0.000 description 19
- 230000000694 effects Effects 0.000 description 18
- 229940068196 placebo Drugs 0.000 description 18
- 239000000902 placebo Substances 0.000 description 18
- 208000007106 Menorrhagia Diseases 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 11
- -1 clays Polymers 0.000 description 10
- 210000001519 tissues Anatomy 0.000 description 10
- 239000002253 acid Substances 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 7
- 201000004458 myoma Diseases 0.000 description 7
- 210000004291 Uterus Anatomy 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 201000007954 uterine fibroid Diseases 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- WWYNJERNGUHSAO-XUDSTZEESA-N Previfem Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000007891 compressed tablet Substances 0.000 description 4
- 230000035558 fertility Effects 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 229960004400 levonorgestrel Drugs 0.000 description 4
- 238000002595 magnetic resonance imaging Methods 0.000 description 4
- 210000004914 menses Anatomy 0.000 description 4
- 230000005906 menstruation Effects 0.000 description 4
- 230000001850 reproductive Effects 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 210000004369 Blood Anatomy 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 3
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 3
- RJKFOVLPORLFTN-LEKSSAKUSA-N Syngestrets Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 3
- 206010046788 Uterine haemorrhage Diseases 0.000 description 3
- JVBGZFRPTRKSBB-MJBQOYBXSA-N [(8S,11R,13S,14S,17R)-11-[4-(dimethylamino)phenyl]-17-(2-methoxyacetyl)-13-methyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(C(=O)COC)OC(C)=O)=CC=C(N(C)C)C=C1 JVBGZFRPTRKSBB-MJBQOYBXSA-N 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 230000003042 antagnostic Effects 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000001911 anti-progestational Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000036770 blood supply Effects 0.000 description 3
- 230000022534 cell killing Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000001112 coagulant Effects 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 229940079593 drugs Drugs 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000009802 hysterectomy Methods 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 102000003998 progesterone receptors Human genes 0.000 description 3
- 108090000468 progesterone receptors Proteins 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- HMFKFHLTUCJZJO-UHFFFAOYSA-N 2-{2-[3,4-bis(2-hydroxyethoxy)oxolan-2-yl]-2-(2-hydroxyethoxy)ethoxy}ethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCOCC(OCCO)C1OCC(OCCO)C1OCCO HMFKFHLTUCJZJO-UHFFFAOYSA-N 0.000 description 2
- CODDGSIFXYHHJO-UHFFFAOYSA-L 3-[18-(2-carboxyethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoic acid;iron(2+);hydrate Chemical compound O.[Fe+2].[N-]1C2=C(C)C(CCC(O)=O)=C1C=C([N-]1)C(CCC(O)=O)=C(C)C1=CC(C(C)=C1C=C)=NC1=CC(C(C)=C1C=C)=NC1=C2 CODDGSIFXYHHJO-UHFFFAOYSA-L 0.000 description 2
- 210000001015 Abdomen Anatomy 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- HFVMLYAGWXSTQI-QYXZOKGRSA-N Androstenone Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)(C=CC4)[C@@H]4[C@@H]3CC[C@H]21 HFVMLYAGWXSTQI-QYXZOKGRSA-N 0.000 description 2
- 210000001367 Arteries Anatomy 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 2
- 206010016629 Fibroma Diseases 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical class C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 2
- 229940067606 Lecithin Drugs 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- HCZKYJDFEPMADG-TXEJJXNPSA-N Masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 2
- VKHAHZOOUSRJNA-GCNJZUOMSA-N Mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 2
- 210000000754 Myometrium Anatomy 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- XZEUAXYWNKYKPL-URLMMPGGSA-N Ormeloxifene Chemical compound C1([C@@H]2[C@H](C3=CC=C(C=C3OC2(C)C)OC)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 XZEUAXYWNKYKPL-URLMMPGGSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- RJKFOVLPORLFTN-STHVQZNPSA-N Progesterone Natural products O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1 RJKFOVLPORLFTN-STHVQZNPSA-N 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L Sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- JNYAEWCLZODPBN-CTQIIAAMSA-N Sorbitan Chemical class OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- PYVFWTPEBMRKSR-UHFFFAOYSA-N Tanaproget Chemical compound CN1C(C#N)=CC=C1C1=CC=C(NC(=S)OC2(C)C)C2=C1 PYVFWTPEBMRKSR-UHFFFAOYSA-N 0.000 description 2
- HWKQNAWCHQMZHK-UHFFFAOYSA-N Trolnitrate Chemical compound [O-][N+](=O)OCCN(CCO[N+]([O-])=O)CCO[N+]([O-])=O HWKQNAWCHQMZHK-UHFFFAOYSA-N 0.000 description 2
- 230000003187 abdominal Effects 0.000 description 2
- 238000002679 ablation Methods 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000002800 anti-glucocorticoid Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N benzohydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000000875 corresponding Effects 0.000 description 2
- 238000007257 deesterification reaction Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 230000002357 endometrial Effects 0.000 description 2
- 230000002255 enzymatic Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 230000000670 limiting Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229960003248 mifepristone Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 230000000051 modifying Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 230000003000 nontoxic Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 229960003327 ormeloxifene Drugs 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 239000000583 progesterone congener Substances 0.000 description 2
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002195 synergetic Effects 0.000 description 2
- 238000007669 thermal treatment Methods 0.000 description 2
- GYDJEQRTZSCIOI-LJGSYFOKSA-N (1r,4r)-4-(aminomethyl)cyclohexane-1-carboxylic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8S,11R,13R,14S,17S)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- NVUUMOOKVFONOM-GPBSYSOESA-N 19-Norprogesterone Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 NVUUMOOKVFONOM-GPBSYSOESA-N 0.000 description 1
- OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 1
- XLMXUUQMSMKFMH-UZRURVBFSA-N 2-hydroxyethyl (Z,12R)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCCO XLMXUUQMSMKFMH-UZRURVBFSA-N 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N 2-stearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N 3-Mercaptopropane-1,2-diol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- YJISHJVIRFPGGN-UHFFFAOYSA-N 5-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy-6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)O)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 YJISHJVIRFPGGN-UHFFFAOYSA-N 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L 7681-57-4 Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229960004308 ACETYLCYSTEINE Drugs 0.000 description 1
- 210000003815 Abdominal Wall Anatomy 0.000 description 1
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N Aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000007502 Anemia Diseases 0.000 description 1
- GJMNAFGEUJBOCE-MEQIQULJSA-N Asoprisnil Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@]([C@]3(C2)C)(COC)OC)=CC=C(\C=N\O)C=C1 GJMNAFGEUJBOCE-MEQIQULJSA-N 0.000 description 1
- 229950003620 Asoprisnil Drugs 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- FSVCELGFZIQNCK-UHFFFAOYSA-N Bicine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 1
- 230000035639 Blood Levels Effects 0.000 description 1
- 229940043253 Butylated Hydroxyanisole Drugs 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical class CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 229960005069 Calcium Drugs 0.000 description 1
- 229960003563 Calcium Carbonate Drugs 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L Calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 210000003679 Cervix Uteri Anatomy 0.000 description 1
- 210000002808 Connective Tissue Anatomy 0.000 description 1
- 229960001305 Cysteine Hydrochloride Drugs 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-isoascorbic acid Chemical compound OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K Dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
- 108010084340 Gonadotropin-Releasing Hormone Proteins 0.000 description 1
- 206010061992 Haemophilia Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 229940060367 Inert Ingredients Drugs 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L Magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 229960003951 Masoprocol Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N Mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N Meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 210000002464 Muscle, Smooth, Vascular Anatomy 0.000 description 1
- 210000003205 Muscles Anatomy 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinylpyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 229940049964 Oleate Drugs 0.000 description 1
- 229950011093 Onapristone Drugs 0.000 description 1
- 208000000450 Pelvic Pain Diseases 0.000 description 1
- 210000003200 Peritoneal Cavity Anatomy 0.000 description 1
- 240000005158 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 229920002675 Polyoxyl Polymers 0.000 description 1
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 229940069328 Povidone Drugs 0.000 description 1
- 208000002787 Pregnancy Complications Diseases 0.000 description 1
- 229940075579 Propyl Gallate Drugs 0.000 description 1
- XWGJFPHUCFXLBL-UHFFFAOYSA-M Rongalite Chemical compound [Na+].OCS([O-])=O XWGJFPHUCFXLBL-UHFFFAOYSA-M 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N Saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N Silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L Sodium thiosulphate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 240000001016 Solanum tuberosum Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229940044609 Sulfur Dioxide Drugs 0.000 description 1
- 229950001471 Tanaproget Drugs 0.000 description 1
- 206010057040 Temperature intolerance Diseases 0.000 description 1
- CWERGRDVMFNCDR-UHFFFAOYSA-N Thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N Tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229940116362 Tragacanth Drugs 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 206010047715 Von Willebrand's disease Diseases 0.000 description 1
- QIJRTFXNRTXDIP-JIZZDEOASA-N [(1R)-1-carboxy-2-sulfanylethyl]azanium;chloride;hydrate Chemical compound O.Cl.SC[C@H](N)C(O)=O QIJRTFXNRTXDIP-JIZZDEOASA-N 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- MLSVJHOYXJGGTR-UHFFFAOYSA-N acetic acid;N-[1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbon Chemical compound CC(O)=O.N1C(=O)C(CC=2C=CC(O)=CC=2)NC(=O)CCSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(=O)N)NC(=O)C1CC1=CC=CC=C1 MLSVJHOYXJGGTR-UHFFFAOYSA-N 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 231100000494 adverse effect Toxicity 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 229940087168 alpha Tocopherol Drugs 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 201000000736 amenorrhea Diseases 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940027983 antiseptics and disinfectants Quaternary ammonium compounds Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N azanium;hydron;carbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229910052570 clay Inorganic materials 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000002596 correlated Effects 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- NFLWUMRGJYTJIN-PNIOQBSNSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-PNIOQBSNSA-N 0.000 description 1
- 229960004281 desmopressin Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940109738 hematin Drugs 0.000 description 1
- 229910052595 hematite Inorganic materials 0.000 description 1
- 239000011019 hematite Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229960004337 hydroquinone Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 229940026239 isoascorbic acid Drugs 0.000 description 1
- 230000002147 killing Effects 0.000 description 1
- 238000002357 laparoscopic surgery Methods 0.000 description 1
- 230000002045 lasting Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- 230000002503 metabolic Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
- 239000008184 oral solid dosage form Substances 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N palmityl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 239000000546 pharmaceutic aid Substances 0.000 description 1
- 239000008180 pharmaceutical surfactant Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001184 potassium carbonate Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000012254 powdered material Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 150000003146 progesterones Chemical class 0.000 description 1
- ZTHYODDOHIVTJV-UHFFFAOYSA-N propyl 3,4,5-trihydroxybenzoate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 150000003378 silver Chemical class 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000001187 sodium carbonate Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 235000010269 sulphur dioxide Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 229940035024 thioglycerol Drugs 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- 239000011778 trisodium citrate Substances 0.000 description 1
- 239000000029 vaginal gel Substances 0.000 description 1
- 239000006213 vaginal ring Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Abstract
Disclosed is the use of ulipristal acetate, or any metabolite thereof selected from the group comprising CDB-3877, CDB-3963, CDB-3236, and CDB-4183, in the manufacture of a medicine for normalizing menstrual bleeding on the long-term in a subject suffering from uterine fibroids and/or adenomyosis, wherein the treatment related to normalizing menstrual bleeding comprises administering, before undergoing a vascular occlusion method or a thermal related treatment method, a dosage of ulipristal acetate, or any metabolite thereof. herein the treatment related to normalizing menstrual bleeding comprises administering, before undergoing a vascular occlusion method or a thermal related treatment method, a dosage of ulipristal acetate, or any metabolite thereof.
Description
Treatment of excessive menstrual bleeding associated with uterine fibroids
TECHNICAL FIELD
The present invention relates generally to gynecological diseases and in particular to a
methods and compositions for reducing heavy menstruation associated with said gynecological
diseases following treatment with vascular occlusion methods or thermal related treatment
methods.
BACKGROUND OF THE INVENTION
Many patients suffering from gynecological diseases such as fibroids and/or adenomyosis
require intervention in order to improve the diseases’ symptoms. Usually, treatment choice is
guided by the patient’s age and desire to preserve fertility and/or her uterus.
Over the last few years a variety of non invasive treatments has become available to
women with symptomatic fibroids and provides alternatives to the surgery. For example, Uterine
artery embolization (UAE) which was first described in 1995 (Ravina JH, Bouret JM, Fried D et
al. Value of preoperative embolization of uterine fibroma: report of a multicenter series of 31
cases. Contracept Fertil Sex 1995; 23: 45-49., and since then this method has become widely
used to treat or treating gynecological diseases such as for example fibroids, or more recently
adenomyosis, as a less invasive alternative to hysterectomy.
Besides UAE and transvaginal uterine artery occlusion, thermal related treatment methods have
provided additional minimally invasive options such as percutaneous laser treatment,
cryoablation, thermal myolysis with laser and magnetic resonance imaging (MRI) -guided
focused ultrasound.
Overall, clinical studies of UAE patients with fibroids have reported an improvement in
menstrual bleeding scores but a significant proportion of patients bleeding is not normalized
following the procedure.
On the other hand, the use of anti-progestational agents before a surgical treatment has also been
proposed to shrink uterine leiomoymata (WO2007/103510) or to render the patient amenorrheic.
The above discussion of background art is included to explain the context of the
present invention. It is not to be taken as an admission that any of the documents or other
material referred to was published, known or part of the common general knowledge at the
priority date of any one of the claims of this specification.
Thus, there remain significant unmet needs for efficient and better long-term therapies
for normalizing menstrual bleeding in a patient suffering from a benign gynecological disease
and undergoing a vascular occlusion method or thermal related treatment method.
SUMMARY OF THE INVENTION
According to a broad form of the invention, there is provided the use of ulipristal
acetate, or any metabolite thereof selected from the group comprising CDB-3877, CDB-3963,
CDB-3236, and CDB-4183, in the manufacture of a medicine for normalizing menstrual
bleeding on the long-term in a subject suffering from uterine fibroids and/or adenomyosis,
wherein the treatment related to normalizing menstrual bleeding comprises administering,
before undergoing a vascular occlusion method or a thermal related treatment method, a
dosage of ulipristal acetate, or any metabolite thereof.
The present invention provides a method for normalizing menstrual bleeding on the
long-term in a subject suffering from a benign gynecological disease comprising
administering, before and/or concomitantly and/or after undergoing a vascular occlusion
method or a thermal related treatment method, a dosage of a progesterone receptor modulator,
or any metabolite thereof.
Also provided is a progesterone receptor modulator, or any metabolite thereof, for use
in normalizing menstrual bleeding on the medium term and/or long-term in a subject suffering
from a benign gynecological disease characterized in that said progesterone receptor
modulator, or any metabolite thereof, is administered, before and/or concomitantly and/or after
undergoing a vascular occlusion method or a thermal related treatment method.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to a method for normalizing menstrual bleeding on the
medium term and/or the long-term in a subject suffering from a gynecological disease
comprising administering, before and/or concomitantly and/ or after undergoing a vascular
occlusion method or a thermal related treatment method, a dosage of a progesterone receptor
modulator, or any metabolite thereof.
In a preferred embodiment the invention relates to a method for normalizing menstrual
bleeding on the long-term in a subject suffering from a benign gynaecological disease associated
with menorrhagia comprising administering, before and/or concomitantly and /or after
undergoing a vascular occlusion method or a thermal related treatment method, a dosage of a
progesterone receptor modulator, or any metabolite thereof.
In still a preferred embodiment of the invention the dosage is provided daily.
In a further embodiment, the present invention provides a progesterone receptor
modulator, or any metabolite thereof, for use in normalizing menstrual bleeding on the medium
term and/or long-term in a subject suffering from a benign gynecological disease characterized in
that said progesterone receptor modulator, or any metabolite thereof, is administered, before
and/or concomitantly and/or after undergoing a vascular occlusion method or a thermal related
treatment method.
“Administering”, as it applies in the present invention, refers to contact of a
therapeutically effective amount of a progesterone receptor modulator, a SPRM, or an active
metabolite thereof, to the subject.
The term “normalization” can be defined as a return to a menstrual bleeding which is
considered as of normal or weak strength. If objective measures are used normalization would
imply reduction of menstrual blood loss to < 80ml per menstrual cycle.
The term “medium-term” in relation to the expression “normalizing menstrual bleeding”
refers to a period of approximately 3 months or longer, and long-term refers to a period of
approximately 6 months or longer.
Usually, the “subject” is well-recognized in the art, and, is used herein to refer to a
mammal, and, more preferably, a human being, and even more preferably a human female.
The term “comprise” or “comprising“ is generally used in the sense of include/including,
that is to say permitting the presence of one or more features or components. Additionally, the
term “comprising” also encompasses the term “consisting”.
As used in the specification and claims, the singular form “a”, “an” and “the” include
plural references unless the context clearly dictates otherwise.
As used herein, “at least one” means “one or more.”
The gynecological disease of the present invention will be selected among the group
comprising uterine fibroids and adenomyosis, or a combination of these two diseases.
Uterine fibroids are benign non-cancerous tumors that originate from the smooth muscle
layer, the myometrium and the accompanying connective tissue of the uterus. Uterine fibroids
are also known as uterine leiomyoma, myoma, fibromyoma, leiofibromyoma, fibroleiomyoma,
and fibroma. Fibroids are the most common benign tumors in females with a prevalence of 20–
40% in women of reproductive age (Wallach EE, Vlahos NF. Uterine myomas: an overview of
development, clinical features, and management. Obstet Gynecol 2004; 104: 393–406).
Most fibroids are asymptomatic but nearly half of women with fibroids have significant and
often disabling symptoms including menorrhagia, pelvic pain, dysmenorrhea and pressure
effects. In addition, fibroids that distort the uterine cavity can have adverse effects on fertility
(American Society for Reproductive Medicine. Myomas and reproductive function. Fertil Steril
2008; 90: 125-130 and Somigliana E, Vercellini P, Daguati R, et al. Fibroids and female
reproduction: a critical analysis of the evidence. Hum Reprod Update 2007; 13: 465-76 and
Kolankaya A, Arici A. Myomas and assisted reproductive technologies: when and how to act?
Obstet Gynecol Clin North Am 2006; 33: 145-52 and Donnez J, Jadoul P. What are the
implications of myomas on fertility? A need for a debate? Hum Reprod 2002; 17: 1424-30.).
In such women, heavy uterine bleeding is a leading reason for medical consultation, surgery and
work days lost (Collins J, Crosignani PG. Endometrial bleeding. Hum Reprod Update 2007; 13:
421-31).
As described supra, Uterine artery embolization (UAE) has become a method of choice
for treating gynecological diseases such as for example fibroids as a less invasive alternative to
hysterectomy. However, UAE alleviate bleeding symptoms in only a few patients over a long-
term period.
Adenomyosis, also known as endometriosis interna, is characterized by the presence of
ectopic glandular tissue found in muscle. It usually refers to ectopic endometrial tissue (the
inner lining of the uterus) within the myometrium (the thick, muscular layer of the uterus). The
condition is typically found in women between the ages of 35 and 50. Patients with adenomyosis
can have painful and/or excessive bleeding (menorrhagia). Although minimally invasive
therapies have been used to manage adenomyosis, hysterectomy is considered the only procedure
that definitely cures the disease. Reports of UAE for adenomyosis have described mainly short-
term results (Grow DR, Filer RB. Treatment of adenomyosis with long-term GnRH analogues: a
case report. Obstet Gynecol 1991; 78: 538 -539) some authors suggesting that UAE resulted in
treatment failure (Goodwin SC, McLucas B, Lee M, et al. Uterine artery embolization for the
treatment of uterine leiomyomata: midterm results. J Vasc Interv Radiol 1999; 10: 1159 -1165;
Smith SJ, Sewall LE, Handelsman A. A clinical failure of uterine fibroid embolization due to
adenomyosis. J Vasc Interv Radiol 1999; 10: 1171 -1174). For example, Pelage et al (Pelage JP,
Jacob D, Fazel A, et al. Midterm results of uterine artery embolization for symptomatic
adenomyosis: initial experience. Radiology 2005; 234: 948 -953) reported that only five of nine
patients who underwent UAE for pure adenomyosis had complete resolution of abnormal
bleeding after 24 months.
Since about 35 to 55% of patients suffering from adenomyosis have coexisting fibroids (Siskin
GP, Tublin ME, Stainken BF, Dowling K, Dolen EG. Uterine artery embolization for the
treatment of adenomyosis: clinical response and evaluation with MRI. AJR 2001; 177: 297 -
302), the present invention also considers a method for normalizing menstrual bleeding on the
long-term in a subject suffering from a gynecological disease wherein the gynecological disease
is uterine fibroids and adenomyosis.
The gynecological diseases of the invention are usually treated by vascular occlusion or
by thermal related treatment method.
Non limiting examples of vascular occlusion methods comprise uterine artery
embolization (UAE) and uterine artery occlusion. UAE method can for example be transvaginal,
abdominal or per laparoscopy.
Uterine Artery Embolization, also called Uterine fibroid embolization (UFE) is a minimally
invasive treatment for gynecological disease, in particular for fibroids. In a UFE procedure,
physicians use an x-ray camera called a fluoroscope to guide the delivery of small particles to the
uterus and fibroids. The small particles are injected through a thin, flexible tube called a catheter.
These block the arteries that provide blood flow, causing the fibroids to shrink. Nearly 90% of
women with fibroids experience relief of their symptoms. Because the effect of uterine fibroid
embolization on fertility is not fully predictable, UFE is typically offered to women who no
longer wish to become pregnant.
Transvaginal temporary uterine artery occlusion is an alternative method of reducing blood flow
in the uterine arteries for the treatment of uterine fibroids. The procedure is performed by placing
a Doppler ultrasound-enabled transvaginal clamp in the vaginal fornices and, guided by Doppler
ultrasound auditory signals, positioning it to occlude the arteries by mechanical compression
against the cervix. The clamp is left in place for 6 hours and then removed. Potential advantages
of this technique over UAE are no radiation exposure, no risk of non-target embolization, and the
absence of significant post-procedure pain in most patients (Tropeano G, Amoroso S, Scambia
G. Non-surgical management of uterine fibroids. Hum.Reprod.Update 2008; 14 (3): 259-274)
As used herein, thermal related treatment method refers to a method selected from the
non limiting group comprising thermal myolysis with laser, percutaneous laser treatment,
radiofrequency treatment, cryomyolysis, and magnetic resonance-guided focused ultrasound.
In case of fibroids, myolysis involves the use of a laser to directly damage the myoma cells and
vessels responsible for the myoma blood supply by coagulative necrosis. This may cause the
fibroid to shrink and eventually fibroid cells to necrose. Myolysis is one of the less invasive
options for the treatment of uterine fibroids. It is generally recommended for smaller fibroids,
but not as helpful for larger ones. The treatment is not usually recommended for patients who
hope to have children, because it can cause serious pregnancy complications; these can be
dangerous to both mother and child, such as uterine scarring and infection.
During the treatment, a patient is given anesthesia and then a laparoscope is introduced in the
peritoneal cavity (or an hysteroscope is inserted in the uterus). Next, a laser or high frequency
electric current is administered to the fibroid itself, to directly damage the myoma cells by
coagulative necrosis. This acts to cut off the blood supply to the fibroid without doing the same
to the surrounding tissue. Once the blood supply to the fibroid is cut off, the fibroid ceases
growing, shrinks, and eventually dies.
In the MRI guided percutaneous laser treatment of uterine fibroids, needles are inserted under
MR guidance into the centre of the targeted uterine fibroid through an area of skin that has been
anaesthetized. Bare laser fibers are inserted down the center of each of the needles into the
targeted fibroid. Laser energy is then used to destroy the fibroid. The use of the lasers
percutaneously under MR guidance enables the doctor to accurately target the fibroids before
applying the thermal energy. MR imaging allows thermal recording of the fibroid in real time
throughout the treatment using the heat sensitivity of the MR signal, minimizing damage to the
surrounding area.
The radiofrequency ablation method is performed by using an electrical current instead of a
laser. It is a minimally invasive technique that uses a needle-like device to heat the fibroid with
low frequency electrical current. This technique, called the Halt procedure, begins with the
insertion of a laparoscopic camera into the abdomen to visualize the abdomen. An intra-
abdominal ultrasound probe is inserted through a second incision to determine the size and
location of the fibroids. A third incision, three in total, is used to insert the Halt device. The
device burns the cells, which are later reabsorbed by the body. This is an outpatient procedure,
but it does require general anesthesia.
Another method of uterine fibroid treatment, called cryomyolysis, utilizes a similar technique,
but instead of a laser or electrical current, liquid nitrogen is used to freeze the tissue. This also
causes it to stop growing and shrink to a less disruptive size.
MRI-guided focused ultrasound (MRgFUS) is a new minimally invasive method of thermal
treatment for treating fibroids that received the FDA approval in 2004. With this technique, high-
intensity ultrasound waves pass through the anterior abdominal wall and converge into a precise
target point within the fibroid to cause a temperature rise (55-90°C) sufficient to induce
coagulative necrosis within a few seconds. Concurrent MRI allows accurate tissue targeting and
real time temperature feedback, thereby achieving controlled localized thermal treatment. The
treatment itself consists of consecutive exposures to focused ultrasound energy (sonications)
each one lasting ~20s and resulting in a small (~0.5cm ) bean shaped ablated volume. Between
sonications there is a pause of ~90s to elapse for the tissue to return to its baseline temperature.
Multiple sonications are required to cover the entire target volume, which is typically limited to a
maximum of 150cm of tissue and total procedure time is usually over 3h. Patients are usually
discharged home ~1 hour after the end of the procedure and return to usual activities, on average,
within 48h.
Preferably, the progesterone receptor modulator of the invention is a selective
progesterone receptor modulator (SPRM), or any metabolite thereof. As used herein “a selective
progesterone receptor modulator” or “SPRM” represents a class of progesterone receptor ligands
that exerts clinically relevant tissue-selective progesterone agonist, antagonist, or partial (mixed)
agonist/antagonist effects on various progesterone target tissues in an in- vivo situation
depending on the biological action studied (Smith CL and O'Malley BW, Coregulator function: a
key to understanding tissue specificity of selective receptor modulators in Endocr Rev 2004; 25:
45-71.)
Also preferably, the SPRM of the invention is ulipristal (acetate), formerly known as
CDB-2914. The chemical formula of uliprital is 17α-acetoxy-l lβ-[4-N, N-dimethylamino-
phenyl)norpregna- 4, 9-diene-3, 20-dione. It is a well-known steroid, more specifically a 19-
norprogesterone, which possesses antiprogestational and antiglucocorticoidal activity. This
compound, and methods for its preparation, are described in U. S. Patent Nos. 4,954, 490, 5,
073,548, and 5,929, 262, and international patent applications WO2004/065405 and
WO2004/078709. Properties of this compound are further described in (Blithe DL, Nieman LK,
Blye RP, Stratton P, Passaro M. Development of the selective progesterone receptor modulator
CDB-2914 for clinical indications. Steroids 2003; 68: 1013-1017).
An “active metabolite”, as used herein, refers to a product produced through metabolism
in the body of a specified compound, in the present case a PRM or a SPRM, or salt thereof and
which exhibits the same biological activity as the specified PRM or SPRM.
Throughout the specification (description and claims) and for the ease of reading, the
terms “progesterone receptor modulator”, “selective progesterone receptor modulator (SPRM)”,
and “metabolite thereof”, refer also to the salts of said respective progesterone receptor
modulator, selective progesterone receptor modulator or metabolite thereof.
Active metabolites of ulipristal, or of a salt thereof, may be identified using routine
techniques known in the art and their activities determined using tests such as those described
herein. Such metabolites may result for example from the oxidation, reduction, hydrolysis,
amidation, deamidation, esterification, deesterification, enzymatic cleavage, and the like, of the
administered ulipristal or of a salt thereof. Accordingly, the invention includes active metabolites
of ulipristal or of a salt thereof, including compounds produced by a process comprising
contacting a compound of this invention with a mammal for a period of time sufficient to yield a
metabolic product thereof. Such metabolite may also be produced in vitro by oxidation,
reduction, hydrolysis, amidation, deamidation, esterification, deesterification, or enzymatic
cleavage of the corresponding ulipristal or salt thereof. Examples of metabolites of ulipristal
(CDB-2914), include those described in Attardi BJ, Burgenson J, Hild SA, Reel JR. In vitro
antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding
of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone.
J.Steroid Biochem.Mol.Biol. 2004; 88: 277-288. e.g. monodemethylated CDB-2914 (CDB-
3877) ; didemethylated CDB-2914 (CDB-3963) ; 17 alpha-hydroxy CDB-2914 (CDB-3236) ;
aromatic A-ring derivative of CDB-2914 (CDB-4183).
The progesterone receptor modulator, the SPRM, or a metabolite thereof, may be
administered by any convenient route, including oral, buccal, sublingual, parenteral, transdermal,
vaginal, rectal, etc. For a brief review of present methods for drug delivery, see, Langer, Science
1990; 249: 1527-1533, which is incorporated herein by reference. Methods for preparing
administrable compounds are known or are apparent to those skilled in the art and are described
in more detail in, for example, Remington's Pharmaceutical Science, 17th Ed., Mack Publishing
Company, Easton, Pa. (1985), which is incorporated herein by reference, and which is
hereinafter referred to as “Remington.”
Unit dosages of immediate-release formulations are preferred.
For solid compositions, conventional nontoxic solid carriers may be used which include, for
example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium
saccharine, talcum, cellulose, glucose, sucrose. For oral administration, a pharmaceutically
acceptable nontoxic composition is formed by incorporating any of the normally employed
excipients, such as those carriers previously listed.
The mode of administration possibilities include tablets, capsules, lozenges, pills, transdermal
patches, dental pastes, suppositories, inhalants, solutions, ointments , parenteral depots, vaginal
rings, vaginal gels and intra-uterine delivery systems.
Oral solid dosage forms are preferentially compressed tablets or capsules. Compressed tablets
may contain diluents to increase the bulk of the progesterone receptor modulator, the SPRM, or a
metabolite thereof, so that production of a compressed tablet of practical size is possible.
Binders, which are agents which impart cohesive qualities to powdered materials may be also
necessary. Povidone, starch, gelatin, sugars such as lactose or dextrose, and natural and synthetic
gums may be used. Disintegrants are generally necessary in the tablets to facilitate break-up of
the tablet. Disintegrants include starches, clays, celluloses, algins, gums and crosslinked
polymers. Lastly small amounts of materials known as lubricants and glidants are included in the
tablets to prevent adhesion of the tablet material to surfaces in the manufacturing process and to
improve the flow characteristics of the powder material during manufacture. Colloidal silicon
dioxide is most commonly used as a glidant and compounds such as talc, magnesium stearate or
stearic acids are most commonly used as lubricants. Procedures for the production and
manufacture of compressed tablets are well known by those skilled in the art (See Remington).
Capsules are solid dosage forms using preferentially either a hard or soft gelatin shell as a
container for the mixture of the progestogen agent or progesterone receptor modulator and inert
ingredients. Procedures for production and manufacture of hard gelatin and soft elastic capsules
are well known in the art (See Remington).
The oral route is preferred. Other routes of administration can be suitable in comparison with
oral routes using blood levels to provide clinical success.
In cases where the progesterone receptor modulator, a SPRM, or a metabolite thereof, is included
in a solution, the formulation may contain suspending agents, as for example, ethoxylated
isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose,
aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances,
among others.
Useful intranasal formulations of a progesterone receptor modulator, a SPRM, or a metabolite
thereof may contain at least one stabilizer and/or one surfactant. Among the pharmaceutically
acceptable surfactants are polyoxyethylene castor oil derivatives, such as polyoxyethylene-
glycerol- triricinoleate, also known as polyoxyl 35 caster oil (CREMOPHOR EL), or poloxyl 40
hydrogenated castor oil (CREMOPHOR RH40) both available from BASF Corp.; mono-fatty
acid esters of polyoxyethylene (20) sorbitan, such as polyoxyethylene (20) sorbitan monolaurate
(TWEEN 80), polyoxyethylene monostearate (TWEEN 60), polyoxyethylene (20) sorbitan
monopalmitate (TWEEN 40), or polyoxyethylene 20 sorbitan monolaurate (TWEEN 20) (all
available from ICI Surfactants of Wilmington, Del.); polyglyceryl esters, such as polyglyceryl
oleate; and polyoxyethylated kernel oil (LABRAFIL, available from Gattefosse Corp.).
Preferably, the surfactant will be between about 0.01% and 10% by weight of the pharmaceutical
composition. Among the pharmaceutically useful stabilizers are antioxidants such as sodium
sulfite, sodium metabisulfite, sodium thiosulfate, sodium formaldehyde sulfoxylate, sulfur
dioxide, ascorbic acid, isoascorbic acid, thioglycerol, thioglycolic acid, cysteine hydrochloride,
acetyl cysteine, ascorbyl palmitate, hydroquinone, propyl gallate, nordihydroguaiaretic acid,
butylated hydroxytoluene, butylated hydroxyanisole, alpha-tocopherol and lecithin. Preferably,
the stabilizer will be between about 0.01% and 5% by weight of the pharmaceutical composition.
Suspensions may also include chelating agents such as ethylene diamine tetraacetic acid, its
derivatives and salts thereof, dihydroxyethyl glycine, citric acid and tartaric acid among others.
Additionally, proper fluidity of a suspension can be maintained, for example, by the use of
coating materials such as lecithin, by the maintenance of the required particle size in the case of
dispersions and by the use of surfactants, such as those previously mentioned. Solid dosage
forms for oral administration include capsules, tablets, pills, powders and granules. In such solid
dosage forms, the active compound may be mixed with at least one inert, pharmaceutically
acceptable excipient or carrier, such as sodium citrate or dicalcium phosphate and/or (a) fillers or
extenders such as starches, lactose, sucrose, glucose, mannitol and silicic acid; (b) binders such
as carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and acacia; (c)
humectants such as glycerol; (d) disintegrating agents such as agar-agar, calcium carbonate,
potato or tapioca starch, alginic acid, certain silicates and sodium carbonate; (e) solution
retarding agents such as paraffin; (f) absorption accelerators such as quaternary ammonium
compounds; (g) wetting agents such as cetyl alcohol and glycerol monostearate;(h) absorbents
such as kaolin and bentonite clay; and (i) lubricants such as talc, calcium stearate, magnesium
stearate, solid polyethylene glycols, sodium lauryl sulfate and mixtures thereof. In the case of
capsules, tablets and pills, the dosage form may also comprise buffering agents.
Preferably the amount of progesterone receptor modulator, SPRM, or a metabolite
thereof is effective to normalize menstrual bleeding on the long-term in a mammal suffering
from a gynecological disease and undergoing a vascular occlusion method or a thermal related
treatment method, without clinically significant antiglucocorticoid activity.
Preferably, the SPRM, or any metabolite thereof, is selected from the list comprising
CDB-2914, mifepristone, asoprisnil, proellex, onapristone, org33628, tanaproget, tanaproget-
combo, WAY 166989, NSP 989, NSP-combo, 11[beta]-((4-N,N-Dimethylamino)-phenyl-
17[beta]-hydroxy-17[alpha]-propinyl-4,9(10)-estradienone-(RU-38486), 11[beta]-((4-N,N-
dimethylamino)-phenyl)-17[beta]-hydroxymethyl-17[alpha]-propinyl-4,9(10)-estradien
one, 11[beta]-((4-N,N-dimethylamino)-phenyl)-17[alpha][beta]-hydroxy-17a[alpha]-propinyl-D-
homo-4,9(10),16-estratienone, 11[beta]-p-methoxyphenyl-17[beta]-hydroxy-17[alpha]-
ethinyl-4,9(10)-estradienone, 11[beta]-(4-acetylphenyl)-17[beta]-hydroxy-17[alpha]-(prop
inyl)-4,9(10)estradienone, 11[beta]-(4-dimethylaminophenyl)-17[alpha]-hydroxy-17[beta]-(3-
hydroxy-propyl)-13[alpha]-methyl-4,9-gonadienone, (Z)-11[beta]-[4-
(dimethylamino)phenyl]-17[beta]-hydroxy-17[alpha]-(3-hydroxypropenyl)-estrenone-5,
11[beta], 19-(4-acetylphenyl)-17[beta]-hydroxy-17[alpha]-(3-hydroxyprop(Z)-enyl)-4, 9(10)-
estradienone, 11[beta], 19-(4-cyanophenyl)-17[beta]-hydroxy-17[alpha]-(3-hydroxyprop
(Z)-enyl)androstenone or 11[beta], 19-(4-(3-pyridinyl)-o-phenylene)-17[beta]-hydroxy-
17[alpha]-(3-hydroxyprop(Z)-enyl)androstenone, 17[alpha]-acetoxymethoxy-11β-
[4-N,N-dimethylaminophenyl]norpregna-4,9-diene-3,20-dione (CDB 4124).
Most preferably, the selective progesteron receptor modulator is CDB 2914 (Ulipristal), or any
metabolite thereof.
According to this invention, the SPRM, and in particular ulipristal or any metabolite
thereof, will be administered before and/or concomitantly and/or after undergoing a vascular
occlusion method or a thermal related treatment method. This includes the chronic intermittent
regimen in case of longer administration prior to intervention.
Ulipristal, or any metabolite thereof, will be administered preferably daily, by oral route
for a period of 1 to up to 120 days, most preferably for a period of 84 days (12 weeks). This
administration period takes place before, and is finished when the subject is undergoing the
vascular occlusion method or the thermal related treatment method.
Alternatively the administration period starts during a period before the subject is
undergoing the vascular occlusion method or the thermal related treatment methods and is not
finished when said vascular occlusion method or said thermal related treatment method is
performed.
Also alternatively, the administration period starts concomitantly and/or after undergoing
the vascular occlusion method or the thermal related treatment methods.
The applicants have shown a synergistic effect between i) the administration of a progesterone
receptor modulator, a SPRM, or a metabolite thereof, and ii) a vascular occlusion method or a
thermal related treatment method, for providing a long-term normalization of the menstrual
bleeding that lasts or persists at least 6 months after undergoing said vascular occlusion method
or said thermal related treatment method.
As show in Table 2, the number of ulipristal treated patients that had a PBAC score < 75
is considerably higher when the patients had UAE compared to the patients that were not treated
with UAE (Table 2, 3months after treatment stop group 2: 15%, group 3:17% vs group 4: 36%
and group 5:60%).This effect does not result from the mere effects of a treatment with ulipristal
alone (group 3: 17%) and a treatment with UAE alone (group 4: 25%).
Normalization of menstrual bleeding can be assessed by evaluating the menstrual blood
loss (MBL). The man skilled in the art is familiar with methods to evaluate MBL. This
assessment is done by the subject and the treating physician.
MBL evaluation can for example be done by using a diary to assess menstrual blood loss,
or a pictorial blood-loss assessment chart (PBAC). In this case, menstrual bleeding is considered
normalized when the pictorial blood-loss assessment chart (PBAC) score is equal or less than
100, preferably equal or less than 75.
PBAC is a validated self-reporting tool for assessing menstrual blood loss (Higham JM,
O'Brien PM, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. Br.J.Obstet.
Gynaecol. 1990; 97: 734-739.; Janssen CA. A simple visual assessment technique to
discriminate between menorrhagia and normal menstrual blood loss. Eur.J.Obstet. Gynecol.
Reprod. Biol. 1996; 70: 21-22.; Philipp CS, Faiz A, Heit JA et al. Evaluation of a screening tool
for bleeding disorders in a US multisite cohort of women with menorrhagia. American Journal of
Obstetrics and Gynecology 2011; 204: 209.; Zakherah MS, Sayed GH, El-Nashar SA, Shaaban
MM. Pictorial blood loss assessment chart in the evaluation of heavy menstrual bleeding:
Diagnostic accuracy compared to alkaline hematin. Gynecol. Obstet. Invest. 2011; 71: 281-284).
Patients are provided with standardized sanitary materials and record daily on a chart, the
number of tampons and towels used with the degree to which individual items were soiled with
blood (see Appendix for visualisation of a PBAC chart). A slightly stained tampon/towel scores
1. A completely saturated tampon with blood scores 10 and a completely saturated towel with
blood scores 20. PBAC has been correlated with menstrual blood loss assessed by a standard
chemical method i.e. alkaline haematin (r=0.847). Menorraghia is defined as a PBAC > 100
which correspond to a blood loss of > 80 mL. A PBAC of 400 corresponds to a blood loss of
around 300 mL or approximately 80 tampons/towels used.
PBAC has been widely used for evaluating drugs or devices for the treatment of heavy
menstrual bleeding such as desmopressin (Kadir RA, Lee CA, Sabin CA, Pollard D, Economides
DL. DDAVP nasal spray for treatment of menorrhagia in women with inherited bleeding
disorders: A randomized placebo-controlled crossover study. Haemophilia 2002; 8: 787-793.),
tranexamic acid (Kouides P, Kreuz W. Diagnosis and management of inherited von Willebrand
disease in the next decade: a clinical perspective. Thromb. Res. 2009; 124: 1.), ormeloxifene
(Kriplani A, Kulshrestha V, Agarwal N. Efficacy and safety of ormeloxifene in management of
menorrhagia: A pilot study. Journal of Obstetrics and Gynaecology Research 2009; 35: 746-
752.), levonorgestrel IUD (Reid PC, Virtanen-Kari S. Randomised comparative trial of the
levonorgestrel intrauterine system and mefenamic acid for the treatment of idiopathic
menorrhagia: A multiple analysis using total menstrual fluid loss, menstrual blood loss and
pictorial blood loss assessment charts. BJOG Int.J.Obstet.Gynaecol. 2005; 112: 1121-1125;
Kriplani A, Singh BM, Lal S, Agarwal N. Efficacy, acceptability and side effects of the
levonorgestrel intrauterine system for menorrhagia. Int.J.Gynecol.Obstet. 2007; 97: 190-194.),
and device for endometrial ablation (Busfield RA, Farquhar CM, Sowter MC et al . A
randomized trial comparing the levonorgestrel intrauterine system and thermal balloon ablation
for heavy menstrual bleeding. Obstet.Gynecol.Surv. 2006; 61: 444-445.).
The “hematite method” is another possible method of MBL evaluation. It consists in
analyzing the amount of hemoglobin lost during the menstruation, collected in sanitary towels.
Surprisingly enough, the Applicants have shown that long-term normalization of the
menstrual bleeding after undergoing said vascular occlusion method or said thermal related
treatment methods is more important with therapeutically effective dose or amount of 5 to 20 mg
of ulipristal, more important with a dose of 7 to 20 mg.
Particularly preferred dosages are 7mg, 8mg, 9mg, 10mg, 11mg, 12mg, 13mg, 14mg,
15mg, 16mg, 17mg, 18mg, 19 mg and 20mg.
The Applicants have shown that long-term normalization of the menstrual bleeding after
undergoing said vascular occlusion method or said thermal related treatment methods is more
important with therapeutically effective daily dose or daily amount of 7 to 20 mg of ulipristal,
more important with a dose of 7 mg and even more important with a dose of about 10 mg,
compared to 5 mg.
A dose selected from the list of 7mg, 8mg, 9mg, 10mg, 11mg, 12mg, 13mg, 14mg,
15mg, 16mg, 17mg, 18mg, 19 mg or 20mg per day is thus most preferred.
This invention also envisages the use of an SPRM e.g. ulipristal, or a metabolite thereof,
in a pharmaceutically acceptable salt form. Examples of such salts may include sodium,
potassium, calcium, aluminum, gold and silver salts. Also contemplated are salts formed with
pharmaceutically acceptable amines such as ammonia, alkyl amines, hydroxyalkylamines, N-
methylglucamine and the like. Certain basic compounds also form pharmaceutically acceptable
salts, e.g., acid addition salts. For example, pyrido-nitrogen atoms may form salts with strong
acid, while compounds having basic substituents such as amino groups also form salts with
weaker acids. Examples of suitable acids for salt formation are hydrochloric, sulfuric,
phosphoric, acetic, citric, oxalic, malonic, salicylic, malic, fumaric, succinic, ascorbic, maleic,
pamoic, methanesulfonic and other mineral and carboxylic acids well known to those skilled in
the art. The salts are prepared by contacting the free base form with a sufficient amount of the
desired acid to produce a salt in the conventional manner. The free base forms may be
regenerated by treating the salt with a suitable dilute aqueous base solution such as dilute
aqueous NaOH, potassium carbonate, ammonia and sodium bicarbonate. The free base forms
differ from their respective salt forms somewhat in certain physical properties, such as solubility
in polar solvents, but the acid and base salts are otherwise equivalent to their respective free base
forms for purposes of the invention.
All such acid and base salts are intended to be pharmaceutically acceptable salts within the scope
of the invention and all acid and base salts are considered equivalent to the free forms of the
corresponding compounds for purposes of the invention.
Alternatively, or additionally, it will become apparent that ulipristal, or a metabolite
thereof, may be administered alone or in combination with other treatments, therapeutics or
agents, either simultaneously or sequentially dependent upon the condition to be treated. For
example, ulipristal, or a metabolite thereof, in the method of the invention may be administered
in association with a pain killer or iron and/or sequentially with a GnRH agonist or antagonist or
a progesteron.
The present invention also contemplates a kit for normalizing menstrual bleeding on the
long-term in a subject suffering from a benign gynecological disease comprising the
progesterone receptor modulator, or any metabolite thereof, optionally with reagents and/or
instructions for use.
Generally, the Kit comprises a container and a label or package insert on or associated
with the container. Suitable containers include, for example, bottles, vials, syringes, etc. The
containers may be formed from a variety of materials such as glass or plastic. The container
holds the progesterone receptor modulator, or any metabolite thereof of the invention which is
effective for normalizing menstrual bleeding on the long-term in a subject suffering from a
benign gynecological disease. The label or package insert indicates that the composition is used
for treating the condition of the invention.
Those skilled in the art will appreciate that the invention described herein is susceptible
to variations and modifications other than those specifically described. It is to be understood that
the invention includes all such variations and modifications without departing from the spirit or
essential characteristics thereof. The invention also includes all of the steps, features,
compositions and compounds referred to or indicated in this specification, individually or
collectively, and any and all combinations or any two or more of said steps or features. The
present disclosure is therefore to be considered as in all aspects illustrated and not restrictive, the
scope of the invention being indicated by the appended Claims, and all changes which come
within the meaning and range of equivalency are intended to be embraced therein.
Various references are cited throughout this specification, each of which is incorporated herein
by reference in its entirety.
The foregoing description will be more fully understood with reference to the following
Examples. Such Examples, are, however, exemplary of methods of practicing the present
invention and are not intended to limit the scope of the invention.
EXAMPLES
Example 1.
Effect of 5mg and 10mg oral ulipristal acetate therapy prior Uterine Artery Embolization on
uterine fibroids
1. Clinical study
A double-blind, randomized, placebo-controlled study was conducted to evaluate the long term
effect of ulipristal acetate in the treatment of uterine fibroids. Patients included premenopausal
women 18-50 years with heavy uterine bleeding due to uterine fibroids who were eligible for
surgery. These patients met the criteria of a Pictorial Bleeding Assessment Chart (PBAC) score
>100 during days 1-8 of menstruation.
The patients were randomized in a 2:2:1 manner to receive for 12 weeks, either ulipristal acetate
(UPA) 5 mg or ulipristal acetate 10mg or placebo. In addition, all patients received concomitant
iron therapy (1 tablet of 80 mg or iron once daily, Tardyferon®). The reference to 2:2:1 means
that for every 5 patients, two would be randomized to receive UA 5mg, two to receive UA 10mg
and one to receive placebo.
Forty-eight patients received a daily placebo treatment, 95 patients received a daily dose of 5mg
ulipristal acetate (Esmya®), and 98 patients received a daily dose of 10mg ulipristal acetate
(Esmya®). Of these patients, 115 patients did not undergo surgery: 26 patients in the placebo
group (group 1), 48 subjects in the 5mg group (group 2) and 41 subjects in the 10mg group
(group 3). Thirty-three subjects underwent a Uterine Artery Embolization at or after week 13: 4
patients in the placebo group (group 4), 11 patients in the 5mg ulipristal (Esmya®) group (group
) and 18 patients in the 10mg ulipristal (Esmya®) group (group 6).
2. Parameters Assessed
For study enrollment as well as follow-up assessment, menstrual bleeding was assessed using the
pictorial blood loss assessment chart (PBAC) developed by Higham and colleagues (Higham JM,
O'Brien PM, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. Br J Obstet
Gynaecol 1990; 97:734-9). The PBAC is one of the current standard methods used to objectively
estimate menstrual blood loss and diagnose menorrhagia. Abnormal bleeding is defined as
PBAC score >100 over 8 days of menstruation. Normal menstrual bleeding PBAC is < 75.
Amenorrhea is PBAC =0.
- The PBAC score was assessed before treatment (Baseline), at week 13 after the end of
treatment with ulipristal, at 3 months and 6 months after Uterine Artery Embolization.
- The PBAC and the % of patients with a PBAC< 75 was reported before treatment (Baseline),
at week 13 after the end of treatment with ulipristal, at 3 months and 6 months after the treatment
stop.
3. Results
The results are shown in Tables 1 and 2.
Table 1
No UAE with UAE performed after treatment stop ( 13
weeks onwards)
or any other surgery
Placebo Esmya 5 Esmya 10 Placebo Esmya 5 mg Esmya 10 mg
mg mg
Group 1 Group 2 Group 3 Group 4 Group 5 Group 6
n 26 50 41 4 11 16
PBAC at 470 +/- 328 419 +/- 340 +/- 187 722 +/- 347 490 +/- 231 375 +/- 135
baseline* 281
PBAC at 392 +/- 305 13 +/- 69 2 +/- 13 414 +/- 296 25 +/60 0 +/- 0
week 13 of
treatment*
PBAC 3 421 +/- 321 337 +/- 417 +/- 669 241 +/- 96 202 +/- 102 120 +/- 55
months after 300
treatment
stop *
PBAC 6 347 +/- 242 338 +/- 203 +/- 161 243 +/- 181 207 +/- 117 136+/- 70
months after 233
treatment
stop *
*Mean +/- SD
Table 2
No UAE or any other surgery with UAE
Placebo Esmya 5 mg Esmya 10 mg Placebo Esmya 5 mg Esmya 10 mg
Group 1 Group 2 Group 3 Group 4 Group 5 Group 6
n 25 46 38 4 11 16
0% 0% 0% 0% 0% 0%
% Patient
with PBAC <
75 at baseline
17% 98% 97% 50% 100% 100%
% Patient
with PBAC <
75 at week 13
of treatment
9% 15% 17% 25% 36% 60%
% Patient
with PBAC <
75, 3 months
after end of
treatment
18% 17% 26% 25% 27% 53%
% Patient
with PBAC <
75, 6 months
after after
end of
treatment
3.1 All patients had a PBAC score >100 at baseline (Table 1, group 1 to 6) and had severe
bleeding and associated anemia. None of them had normal menstrual bleeding (Table 2, group 1
to 6).
3.2 At week 13, nearly all ulipristal treated patients had a PBAC score < 75 compared to the
placebo patients and had controlled ( no, weak or normal bleeding) menstrual bleeding (Table 2,
group 2:98%, group 3: 97%, group 5:100% and group 6: 100% vs placebo group 1:17% and
placebo group 4:50%).
3.3 At 3 months after the end of treatment with ulipristal acetate or placebo, in the subgroup
of patients who did not have UAE, the number of ulipristal treated patients that had a PBAC
score < 75 is slightly higher compared to the placebo treated patients (Table 2, group 2: 15%,
group 3:17% vs placebo group 1: 9%).
Interestingly, the number of ulipristal treated patients that had a PBAC score < 75 is
considerably higher when the patients had UAE compared to the patients that were not treated
with UAE (Table 2, 3months after treatment stop group 2: 15%, group 3:17% vs group 4: 36%
and group 5:60%).
Therefore, these results demonstrate a synergistic effect for controlling menstrual bleeding
resulting from the oral administration of ulipristal prior to UAE. This effect does not result from
the mere effects of a treatment with ulipristal alone (group 3: 17%) and a treatment with UAE
alone (group 4: 25%).
Interestingly, the number of ulipristal treated patients that had a PBAC score < 75 is
considerably higher when the patients received a 10mg dose of ulipristal prior UAE compared to
the placebo treated patients.
3.5 There is a dose dependence effect that is observed when ulipristal is administered prior
UAE at a dose of 10mg in comparison to 5mg This dose dependence effect is observed at 3
months after UAE (group 6: 60% vs group 5: 36%) and at 6 months after UAE (group 6: 53% vs
group 5: 27%) showing the long term effect of this method for controlling excessive menstrual
bleeding in a patient population with uterine fibroids.
Claims (13)
1. Use of ulipristal acetate, or any metabolite thereof selected from the group comprising CDB-3877, CDB-3963, CDB-3236, and CDB-4183, in the manufacture of a medicine for normalizing menstrual bleeding on the long-term in a subject suffering from uterine fibroids 5 and/or adenomyosis, wherein the treatment related to normalizing menstrual bleeding comprises administering, before undergoing a vascular occlusion method or a thermal related treatment method, a dosage of ulipristal acetate, or any metabolite thereof.
2. The use according to claim 1, wherein the vascular occlusion method is selected from the group comprising uterine artery embolization (UAE) and transvaginal uterine artery 10 embolization.
3. The use according to claim 1 or claim 2, wherein the thermal related treatment method is selected from the group comprising thermal myolysis with laser, percutaneous laser treatment, radiofrequency ablation, cryomyolysis, and magnetic resonance-guided focused ultrasound. 15
4. The use according to any one of claims 1 to 3, wherein the menstrual bleeding is normalized when the menstrual blood loss is reduced to < 80ml per menstrual cycle.
5. The use according to claim 4, wherein the long-term normalization lasts at least 6 months after undergoing said vascular occlusion method or said thermal related method.
6. The use according to any one of claims 1 to 5, wherein CDB 2914 (Ulipristal) or any 20 metabolite thereof is administered in a dosage of 5 to 20 mg.
7. The use according to claim 6, wherein the dosage of CDB 2914 (Ulipristal), or any metabolite thereof, is about 5mg, about 6mg, about 7mg, about 8mg, about 9mg, about 10mg, about 11mg , about 12mg, about 13mg, about 14 mg, about 15mg, about 16mg, about 17mg, about 18mg, about 19mg, or about 20mg. 25
8. The use according to claim 7, wherein the dosage of CDB 2914 (Ulipristal), or any metabolite thereof, is about 5 mg.
9. The use according to claim 7, wherein the dosage of CDB 2914 (Ulipristal), or any metabolite thereof, is about 7 mg.
10. The use according to claim 7, wherein the dosage of CDB 2914 (Ulipristal), or any metabolite thereof, is about 10mg. 5
11. The use according to claims 1 to 10, wherein the subject is a mammal.
12. The use according to claim 11 wherein the mammal is a human being.
13. The use according to any one of claims 6 to 10, wherein the dosage is a daily dosage.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161506704P | 2011-07-12 | 2011-07-12 | |
EP11173630A EP2545922A1 (en) | 2011-07-12 | 2011-07-12 | Treatment of excessive menstrual bleeding associated with uterine fibroids |
EP11173630.2 | 2011-07-12 | ||
US61/506,704 | 2011-07-12 | ||
PCT/IB2012/053577 WO2013008202A1 (en) | 2011-07-12 | 2012-07-12 | Treatment of excessive menstrual bleeding associated with uterine fibroids |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ619478A NZ619478A (en) | 2015-12-24 |
NZ619478B2 true NZ619478B2 (en) | 2016-03-30 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9168264B2 (en) | Treatment of excessive menstrual bleeding associated with uterine fibroids | |
CA2818468C (en) | Treatment of pain associated with dislocation of basal endometrium | |
Gupta et al. | Effect of mifepristone on dilatation of the pregnant and non-pregnant cervix | |
JP2018109025A (en) | Method for treating gynecological diseases | |
Muse | Cyclic pelvic pain | |
NZ619478B2 (en) | Treatment of excessive menstrual bleeding associated with uterine fibroids | |
RO122179B1 (en) | Use of mesoprogestins for the treatment and prevention of benign hormone-dependent gynecological disorders | |
US20190262361A1 (en) | Progesterone Receptor Modulators for Use in the Therapy of Uterine Fibroids | |
WO2012121811A1 (en) | Treatment of excessive menstrual blood loss by intravaginal administration of low doses of antifibronlytic or hemostatic agent | |
CN1845723B (en) | Methods for the treatment of endometriosis | |
Janaki et al. | Uterine fibroid embolization in treatment of symptomatic fibroid uterus |